This paper is in the following e-collection/theme issue:

Grant Proposals (funded, non-ehealth) (69) Clinical Cancer Research (83)

Published on in Vol 4, No 2 (2015): Apr-Jun

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Authors of this article:

Bo Jan Noordman1 Author Orcid Image ;   Joel Shapiro1 Author Orcid Image ;   Manon CW Spaander2 Author Orcid Image ;   Kausilia K Krishnadath3 Author Orcid Image ;   Hanneke WM van Laarhoven4 Author Orcid Image ;   Mark I van Berge Henegouwen5 Author Orcid Image ;   Grard AP Nieuwenhuijzen6 Author Orcid Image ;   Richard van Hillegersberg7 Author Orcid Image ;   Meindert N Sosef8 Author Orcid Image ;   Ewout W Steyerberg9 Author Orcid Image ;   Bas PL Wijnhoven1 Author Orcid Image ;   J Jan B van Lanschot1 Author Orcid Image
Article Authors Cited by (58) Tweetations (1) Metrics

Journals

  1. Noordman B, Verdam M, Onstenk B, Heisterkamp J, Jansen W, Martijnse I, Lagarde S, Wijnhoven B, Acosta C, van der Gaast A, Sprangers M, van Lanschot J. Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer. Annals of Surgical Oncology 2019;26(13):4765 View
  2. Wong I, Law S. Surgery in the era of neoadjuvant therapy for cancer of the esophagus. Esophagus 2016;13(2):105 View
  3. Kathiravetpillai N, Koëter M, van der Sangen M, Creemers G, Luyer M, Rutten H, Nieuwenhuijzen G. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. European Journal of Surgical Oncology (EJSO) 2016;42(8):1183 View
  4. Larue R, Van De Voorde L, Berbée M, van Elmpt W, Dubois L, Panth K, Peeters S, Claessens A, Schreurs W, Nap M, Warmerdam F, Erdkamp F, Sosef M, Lambin P. A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer 2016;16(1) View
  5. A von Döbeln G, Klevebro F, Nilsson M. Reply to letter: Neoadjuvant chemoradiotherapy or chemotherapy for esophageal cancer: what is the current evidence?. Diseases of the Esophagus 2019;32(3) View
  6. Noordman B, Verdam M, Lagarde S, Shapiro J, Hulshof M, van Berge Henegouwen M, Wijnhoven B, Nieuwenhuijzen G, Bonenkamp J, Cuesta M, Plukker J, Spillenaar Bilgen E, Steyerberg E, van der Gaast A, Sprangers M, van Lanschot J. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Annals of Oncology 2018;29(2):445 View
  7. Voncken F, Aleman B, van Dieren J, Grootscholten C, Lalezari F, van Sandick J, Steinberg J, Vegt E. Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer. Strahlentherapie und Onkologie 2018;194(2):156 View
  8. Zhang X, Eyck B, Yang Y, Liu J, Chao Y, Hou M, Hung T, Pang Q, Yu Z, Jiang H, Law S, Wong I, Lam K, van der Wilk B, van der Gaast A, Spaander M, Valkema R, Lagarde S, Wijnhoven B, van Lanschot J, Li Z. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study. BMC Cancer 2020;20(1) View
  9. Klevebro F, Ekman S, Nilsson M. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer – Review article. Surgical Oncology 2017;26(3):290 View
  10. Triantafyllou T, Wijnhoven B. Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation. Annals of Gastroenterological Surgery 2020;4(4):352 View
  11. Larue R, Klaassen R, Jochems A, Leijenaar R, Hulshof M, van Berge Henegouwen M, Schreurs W, Sosef M, van Elmpt W, van Laarhoven H, Lambin P. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncologica 2018;57(11):1475 View
  12. Manur J, Sebastian M, David S. Chemo-radiation outcomes for esophageal cancer: A reflection from a tertiary cancer center on selection of patients for more aggressive therapy. Indian Journal of Cancer 2020;57(1):84 View
  13. Noordman B, Wijnhoven B, Lagarde S, Biermann K, van der Gaast A, Spaander M, Valkema R, van Lanschot J. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer. Diseases of the Esophagus 2017;30(12):1 View
  14. Liw P, Wen Y, Tsai C, Chang H, Tseng C, Hung T, Chao Y. Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy. The Journal of Thoracic and Cardiovascular Surgery 2018;155(5):2233 View
  15. Chao Y, Chang Y, Yeh C, Chang H, Tseng C, Chuang W. Characterization of residual tumours at the primary site in patients with a near pathological complete response after neoadjuvant chemoradiotherapy for oesophageal cancer. British Journal of Surgery 2016;103(13):1874 View
  16. Noordzij I, Curvers W, Huysentruyt C, Nieuwenhuijzen G, Creemers G, van der Sangen M, Schoon E. Salvage endoscopic resection in patients with esophageal adenocarcinoma after chemoradiotherapy. Endoscopy International Open 2018;06(09):E1126 View
  17. Contino G, Vaughan T, Whiteman D, Fitzgerald R. The Evolving Genomic Landscape of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterology 2017;153(3):657 View
  18. Wilk B, Eyck B, Doukas M, Spaander M, Schoon E, Krishnadath K, Oostenbrug L, Lagarde S, Wijnhoven B, Looijenga L, Biermann K, Lanschot J. Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial. British Journal of Surgery 2020;107(13):1791 View
  19. Jhala D. Cytology of the gastrointestinal tract: opportunities to be tapped. Diagnostic Histopathology 2015;21(12):462 View
  20. Luo L, Zhao L, Wang Y, Tian X, Xi M, Shen J, He L, Li Q, Liu S, Zhang P, Xie D, Liu M. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma. Scientific Reports 2015;5(1) View
  21. Arnett A, Merrell K, Macintosh E, James S, Nathan M, Shen K, Ravi K, Neben Wittich M, Haddock M, Hallemeier C. Utility of 18 F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation. Journal of Thoracic Oncology 2017;12(1):121 View
  22. Kuipers E, Spaander M. Natural History of Barrett’s Esophagus. Digestive Diseases and Sciences 2018;63(8):1997 View
  23. Roy A, Shapiro J, Burge M, Karapetis C, Pavlakis N, Segelov E, Chau I, Lordick F, Chen L, Barbour A, Tebbutt N, Price T. Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy 2020;20(4):305 View
  24. Chao Y, Chang H, Tseng C, Liu Y, Wen Y. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. Diseases of the Esophagus 2016 View
  25. Heneghan H, Donohoe C, Elliot J, Ahmed Z, Malik V, Ravi N, Reynolds J. Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?. Annals of Surgery 2016;264(5):831 View
  26. Chao Y, Wen Y, Chang H, Tseng C, Liu Y. An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. European Journal of Surgical Oncology 2017;43(12):2366 View
  27. Noordman B, Wijnhoven B, van Lanschot J. Optimal surgical approach for esophageal cancer in the era of minimally invasive esophagectomy and neoadjuvant therapy. Diseases of the Esophagus 2016;29(7):773 View
  28. Voeten D, den Bakker C, Heineman D, Ket J, Daams F, van der Peet D. Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta‐analyses and Systematic Review of Literature. World Journal of Surgery 2019;43(5):1271 View
  29. Chao Y, Chuang W, Yeh C, Chang H, Tseng C. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy. European Journal of Cardio-Thoracic Surgery 2018;53(1):201 View
  30. Noordman B, Spaander M, Valkema R, Wijnhoven B, van Berge Henegouwen M, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof M, Krishnadath K, Lagarde S, Nieuwenhuijzen G, Oostenbrug L, Siersema P, Schoon E, Sosef M, Steyerberg E, van Lanschot J, Doukas M, Krak N, Poley J, van Rij C, Bergman J, Gisbertz S, van Laarhoven H, Meijer S, Goense L, Haj Mohammad N, Hobbelink M, Offerhaus G, Vleggaar F, Curvers W, Creemers G, Roef M, van der Sangen M, Buijsen J, Riedl R, Schreurs W, Warmerdam F, Janssen M, van der Post C, Radema S, Rosman C, Rütten H. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. The Lancet Oncology 2018;19(7):965 View
  31. Davidson M, Chau I. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. Expert Review of Anticancer Therapy 2018;18(4):327 View
  32. Kamarajah S, Navidi M, Wahed S, Immanuel A, Hayes N, Griffin S, Phillips A. Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction. Annals of Surgical Oncology 2020;27(9):3182 View
  33. Goense L, van Rossum P, Kandioler D, Ruurda J, Goh K, Luyer M, Krasna M, van Hillegersberg R. Stage‐directed individualized therapy in esophageal cancer. Annals of the New York Academy of Sciences 2016;1381(1):50 View
  34. van Olphen S, Biermann K, Shapiro J, Wijnhoven B, Toxopeus E, van der Gaast A, Stoop H, van Lanschot J, Spaander M, Bruno M, Looijenga L. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy. Annals of Surgery 2017;265(2):347 View
  35. Zhang Y, Liu J, Zhang W, Deng W, Yue J. Treatment of esophageal cancer with radiation therapy: a pan-Chinese survey of radiation oncologists. Oncotarget 2017;8(21):34946 View
  36. van Rossum P, Goense L, Meziani J, Reitsma J, Siersema P, Vleggaar F, van Vulpen M, Meijer G, Ruurda J, van Hillegersberg R. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis. Gastrointestinal Endoscopy 2016;83(5):866 View
  37. Jelvehgaran P, Alderliesten T, Georgiou G, Meijer S, Bloemen P, Kodach L, van Laarhoven H, van Berge Henegouwen M, Hulshof M, Rasch C, van Leeuwen T, de Boer J, de Bruin M, van Herk M. Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. Biomedical Optics Express 2018;9(9):4196 View
  38. Sheil F, Donohoe C, King S, O’Toole D, Cunningham M, Cuffe S, Ravi N, Reynolds J. Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?. World Journal of Surgery 2018;42(5):1485 View
  39. Haidry R. Endoluminal resective therapy for residual esophageal neoplasia after definitive chemoradiotherapy: Who are we helping—the patient or the endoscopist?. Gastrointestinal Endoscopy 2021;93(4):899 View
  40. Valkema M, Noordman B, Wijnhoven B, Spaander M, Biermann K, Lagarde S, Bennink R, Schreurs W, Roef M, Hobbelink M, Janssen M, Graven L, van Lanschot J, Valkema R. Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Journal of Nuclear Medicine 2019;60(11):1553 View
  41. Wang S, Marshall M. Chemoradiation Therapy as Definitive Treatment of Esophageal Cancer. Surgical Clinics of North America 2021;101(3):443 View
  42. Bakhos C, Acevedo E, Petrov R, Abbas A. Surveillance Following Treatment of Esophageal Cancer. Surgical Clinics of North America 2021;101(3):499 View
  43. John N, Irodi A, Thomas H, Abraham V, Sasidharan B, John S, Pavamani S. Utility of Mid-treatment DWI in Selecting Pathological Responders to Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Cancer. Journal of Gastrointestinal Cancer 2023;54(2):447 View
  44. Kamarajah S, Evans R, Griffiths E, Gossage J, Pucher P. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by radical surgery for locally advanced oesophageal squamous cell carcinoma: meta-analysis. BJS Open 2022;6(6) View
  45. Dora T, Aeron T, Chatterjee A, Deshmukh J, Goel A, Bose S, Chaudhary D, Sharma R, Khandelwal S, Sancheti S, Pahwa S, Singh A, Saini A, Laskar S, Agarwal J, Shrivastava S, Kapoor R. Neoadjuvant chemoradiotherapy followed by surgery for operable carcinoma esophagus. Cancer Research, Statistics, and Treatment 2021;4(4):647 View
  46. Faiz Z, Kats-Ugurlu G, Mui V, Karrenbeld A, Burgerhof H, Plukker J, Muijs C. Locoregional Residual Esophageal Cancer after Neo-adjuvant Chemoradiotherapy and Surgery Regarding Anatomic Site and Radiation Target Fields. Annals of Surgery 2022;275(6):e759 View
  47. van der Wilk B, Noordman B, Neijenhuis L, Nieboer D, Nieuwenhuijzen G, Sosef M, van Berge Henegouwen M, Lagarde S, Spaander M, Valkema R, Biermann K, Wijnhoven B, van der Gaast A, van Lanschot J, Doukas M, Nikkessen S, Luyer M, Schoon E, Roef M, van Lijnschoten I, Oostenbrug L, Riedl R, Gisbertz S, Krishnadath K, Bennink R, Meijer S. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Surgery 2021;274(6):1009 View
  48. Hofste L, Geerlings M, von Rhein D, Tolmeijer S, Weiss M, Gilissen C, Hofste T, Garms L, Janssen M, Rütten H, Rosman C, van der Post R, Klarenbeek B, Ligtenberg M. Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer. Cancers 2022;14(18):4417 View
  49. Bayley E, Ivy M, Shewale J, Ge P, Antonoff M, Francis A, Hofstetter W, Mehran R, Rajaram R, Rice D, Roth J, Sepesi B, Vaporciyan A, Walsh G, Lee J, Louie B, Swisher S. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation. Annals of Surgery 2023;277(5):721 View
  50. Kamarajah S, Markar S, Low D, Phillips A. Prognostic implications of the extent of downstaging after neoadjuvant therapy for oesophageal adenocarcinoma and oesophageal squamous cell carcinoma. BJS Open 2023;7(3) View
  51. van der Aa D, Gisbertz S, Anderegg M, Lagarde S, Klaassen R, Meijer S, van Dieren S, Hulshof M, Bergman J, Bennink R, van Laarhoven H, van Berge Henegouwen M. 18F-FDG-PET/CT to Detect Pathological Complete Response After Neoadjuvant Treatment in Patients with Cancer of the Esophagus or Gastroesophageal Junction: Accuracy and Long-Term Implications. Journal of Gastrointestinal Cancer 2024;55(1):270 View
  52. van der Zijden C, van der Sluis P, Mostert B, Nuyttens J, van Lanschot J, Spaander M, Valkema R, Coene P, Dekker J, Fiets W, Hartgrink H, Hazen W, Kouwenhoven E, Nieuwenhuijzen G, Rosman C, van Sandick J, Sosef M, van der Zaag E, Lagarde S, Wijnhoven B. Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort Study. Annals of Surgical Oncology 2024;31(12):7759 View
  53. Schmidt I, Zhao X, van der Waaij A, Meersma G, Dijkstra F, Haveman J, van Etten B, Robinson D, Kats-Ugurlu G, Nagengast W. Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy. Clinical Cancer Research 2024;30(15):3211 View

Books/Policy Documents

  1. Thomas M, Haustermans K. Radiation Oncology. View
  2. Boshier P, Wirsching A, Low D. A Mastery Approach to Complex Esophageal Diseases. View
  3. van den Berg J, Lagarde S, Wijnhoven B, van der Gaast A, van Lanschot J. Minimally Invasive Surgery for Upper Abdominal Cancer. View
  4. Chiapponi C, Leers J, Schröder W, Bruns C. Evidenzbasierte Viszeralchirurgie maligner Erkrankungen. View
  5. Noordman B, Lagarde S, Wijnhoven B, van Lanschot J. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set. View